Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker (AUR)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
To determine whether the addition of a dual Five Alpha Reductase Inhitor (Dutasteride) will alleviate urinary retention secondary to BPH in who have failed a voiding trial without a catheter. Following treatment with an Alpha Blocker alone.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
50 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Males betewen the ages of 50 and 90 years of age.Written informed consent.
Men with acute urinary retention attributed to bladder outlet obstruction caused by BPH, who have failed atleast 1 week trial of alpha blocker treatment.
PSA level equal to or greater than 1.5ng/ml and equal to or less than 15 ng/ml.
Urinary retention attributed to a neurogenic or myogenic bladder dysfunction.
Use of psychotrophic medications.
Use of antichollinergic medications.
Allery to five alpha reductase inhibitors.
Prior prostate surgery.
Invasive bladder cancer.
Inability to understand or agree with the requirements of the study.
Any investigational drug received within 30 days prior of study entry.